Clinical management of the multiple endocrine neoplasia syndromes: Results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau Disease

Journal of Internal Medicine

Volumn 243, Issue 6, 1998, Pages 589-594

  Lips, C J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clinical management; Computerized opinion poll; Multiple endocrine neoplasia; Von Hippel Lindau disease

Indexed keywords

CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DETERMINATION; FERTILIZATION IN VITRO; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC COUNSELING; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; VON HIPPEL LINDAU DISEASE; WORKSHOP;

EID: 0031834188     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00375.x     Document Type: Conference Paper

References (10)

1. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi S-E, Collins FS, Emmert-Buck M et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997; 276: 404-7.
2. Lemmens I, Van De Ven WJM, Kas K, Zhang CX, Giraud S, Wautot V et al. The European Consortium on MEN1. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Human Mol Genet 1997; 6: 1177-83.
3. Dong Q, Debelenko L, Chandrasekharappa SC, Emmert-Buck MR, Zhuang Z, Guru SC et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids. lipomas. and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocr Metab 1997; 82: 1416-20.
4. Mulligan LM, Kwok JBJ, Healy CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia syndrome type 2A. Nature 1993; 363: 458-60.
5. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma, Nature 1994; 367: 375-6.
6. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1994; 267: 381-3.
7. Landsvater RM, De Wit MJ, Zewald RA, Hofstra RMW, Buys CHCM, Ploos van Amstel HK et al. Somatic mutations of the Ret proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res 1996; 56: 4853-5.
8. Moers AMJ, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IAJ, Blijham GH et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family; familial medullary thyroid carcinoma revisited. Am J Med 1996; 101: 635-41.
9. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham GH, Jansen-Schillhorn van Veen J et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia syndrome type 2A. N Engl J Med 1994; 331: 828-35.
10. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML et al. Identification of the von Hippel-Landau tumor suppressor gene. Science 1993; 260: 1317-20.